Geode Capital Management’s BioRestorative Therapies BRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-7,621
Closed -$57.3K – 4403
2026
Q2
$57.3K Sell
7,621
-3,533
-32% -$20.7K ﹤0.01% 4216
2026
Q1
$60.7K Buy
11,154
+8,261
+286% +$106K ﹤0.01% 4268
2025
Q4
$67.7K Buy
2,893
+130
+5% +$3.46K ﹤0.01% 4179
2025
Q3
$79K Buy
2,763
+50
+2% +$1.55K ﹤0.01% 4184
2025
Q2
$90.6K Sell
2,713
-287
-10% -$10K ﹤0.01% 4087
2025
Q1
$107K Buy
3,000
+264
+10% +$10.1K ﹤0.01% 4014
2024
Q4
$78.3K Sell
2,736
-49
-2% -$1.52K ﹤0.01% 4157
2024
Q3
$96.9K Buy
2,785
+168
+6% +$5.54K ﹤0.01% 4112
2024
Q2
$106K Buy
2,617
+594
+29% +$17.1K ﹤0.01% 4122
2024
Q1
$55.8K Sell
2,023
-141
-7% -$4.34K ﹤0.01% 4295
2023
Q4
$74K Hold
2,164
– – ﹤0.01% 4265
2023
Q3
$77K Sell
2,164
-25
-1% -$1.26K ﹤0.01% 4318
2023
Q2
$193K Buy
2,189
+1,504
+220% +$144K ﹤0.01% 4060
2023
Q1
$46.6K Hold
685
– – ﹤0.01% 4536
2022
Q4
$37K Buy
685
+69
+11% +$4.3K ﹤0.01% 4671
2022
Q3
$39K Hold
616
– – ﹤0.01% 4811
2022
Q2
$36K Buy
616
+71
+13% +$6.02K ﹤0.01% 4844
2022
Q1
$57K Buy
+545
New +$47K ﹤0.01% 4782

Other funds holding BRTX

Geode Capital Management's BRTX Position: Q3 2026 in Review

Geode Capital Management sold out of BioRestorative Therapies (BRTX) in Q3 2026, closing a stake of 7,621 shares — an estimated $57.3K sold.

Geode Capital Management first reported a position in BRTX in Q1 2022 and held it in 18 quarters. The position peaked at $193K in Q2 2023. 14 funds tracked by Wall St. Rank hold BRTX as of Q3 2026.

  • Geode Capital Management reported no remaining BioRestorative Therapies position as of Q3 2026 after selling out during the quarter.
  • Geode Capital Management sold 7,621 BioRestorative Therapies shares in Q3 2026, an estimated $57.3K.
  • Geode Capital Management first reported a position in BioRestorative Therapies in Q1 2022 and held it in 18 quarters.
  • Geode Capital Management's BioRestorative Therapies position peaked at $193K in Q2 2023.
  • 14 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.